Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study).

What Was Tested

This randomized controlled trial looks at Angiotensin II Type 1 Receptor Blockers.

Recently, obesity patients have been diagnosed as metabolic syndrome.

Who Took Part

The abstract describes 356 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

The patients with metabolic syndrome were enrolled.

A total of 356 patients attending 60 outpatient Japanese centers were recruited.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Angiotensin II Type 1 Receptor Blockers group and the comparison group should start out alike.

Home BP was monitored by using a telemedicine system.

These end points were evaluated by using the telemedicine system during steady-state active therapy.

What Was Measured

The subject headings attached to it are Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Asian People, Benzimidazoles, Benzoates, Biphenyl Compounds and Blood Pressure.

The authors tagged it with the keywords Home blood pressure, hypertension, metabolic syndrome, office blood pressure and telemedicine.

What This Means in Plain Language

The paper is a randomized study of Angiotensin II Type 1 Receptor Blockers in 356 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Clinical and experimental hypertension (New York, N.Y. : 1993)), a journal based in England.

More context: all human trials.